Bernstein Remains Bullish on Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NYSE:NVO) is one of the best undervalued stocks to buy under $50. Bernstein analyst Florent Cespedes reiterated his bullish outlook on Novo Nordisk A/S (NYSE:NVO) on November 4 and set a price target of DKK540.

The same day, Novo Nordisk A/S (NYSE:NVO) announced that it submitted an updated unsolicited proposal for the acquisition of Metsera, Inc, including its early and development-stage incretin and non-incretin analogue peptide programmes.

Management reported that the updated unsolicited proposal was declared “superior” by the board of directors of Matsera, and that the acquisition would provide Novo Nordisk A/S (NYSE:NVO) with the “opportunity to maximise the potential of Metsera’s complementary portfolio and capabilities”.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.